Metformin Aristo

Metformin, the active ingredient in Metformin Aristo, is a biguanide presented as an oral tablet for oral use. It is used to lower elevated blood glucose levels in adults with type 2 diabetes mellitus, improving overall glycemic control and is commonly prescribed as part of a comprehensive diabetes management plan.

GNH USA supplies Metformin Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Metformin Aristo belongs to the biguanide class and is indicated for disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): helps reduce the risk of progression to overt diabetes. - Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity.

Metformin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: marked elevation of liver enzymes. - Hypoglycemia: uncommon when used alone, more likely with concomitant insulin. - Pancreatitis: inflammation of the pancreas.

When prescribing Metformin Aristo, clinicians should consider several safety measures.

- Renal function monitoring: assess creatinine clearance before initiation and periodically. - Hepatic function monitoring: evaluate liver enzymes at baseline and during treatment. - Vitamin B12 levels: check periodically as long‑term use may cause deficiency. - Avoid in severe renal impairment: contraindicated when eGFR <30 mL/min/1.73 m². - Use caution in elderly patients: increased risk of lactic acidosis. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Metformin's pharmacokinetic profile can be altered by several co‑administered medicines.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function when combined. - NSAIDs: may reduce renal perfusion, increasing metformin levels. - Digoxin: requires observation for any unexpected effects.